Adam Kittai, MD, of the Icahn School of Medicine at Mount Sinai, discusses how to approach sequencing pirtobrutinib with chimeric antigen receptor (CAR) T-cell therapy for the treatment of chronic lymphocytic leukemia (CLL) and Richter transformation at the Twelfth Annual Meeting of the Society of Hematologic Oncology.